Google, Johnson & Johnson back protein degrader start-up

Written By Christine Mackenzie

https://cen.acs.org/pharmaceuticals/biologics/Google-Johnson-amp-Johnson-back/104/web/2026/01

Christine Mackenzie
Previous

EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors
Next

Former Genentech leaders’ protein degrader startup nets $107M